LEGN.US (LEGN.US) announced on July 17, 2017, that according to the cooperation and license agreement signed between the company and Janssen on December 21, 2017, LEGEND Biotech announced on July 17, 2024 that in the quarter ending June 30, 2024, CARVYKTI's net sales volume was approximately 0.186 billion US dollars.

CARVYKTI is the first CAR-T product from China approved by the US Food and Drug Administration (FDA). In March 2022, CARVYKTI was officially approved in the US to treat patients with recurrent or refractory multiple myeloma (R/RMM) with dry treatment. Since then, CARVYKTI has been approved for listing in the European Union and Japan.